Provided by Tiger Trade Technology Pte. Ltd.

Akebia Therapeutics

0.9178
+0.01481.64%
Post-market: 0.91850.0007+0.08%17:15 EDT
Volume:7.50M
Turnover:6.85M
Market Cap:254.33M
PE:-8.25
High:0.9362
Open:0.9082
Low:0.8952
Close:0.9030
52wk High:3.20
52wk Low:0.8140
Shares:277.11M
Float Shares:269.24M
Volume Ratio:1.23
T/O Rate:2.79%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1112
EPS(LYR):-0.0208
ROE:-109.38%
ROA:-1.05%
PB:10.17
PE(LYR):-44.16

Loading ...

Akebia Therapeutics Price Target Maintained with a $4.00/Share by BTIG

Dow Jones
·
Sep 15

Akebia Doses First Patient in Phase 2 Ebribafusp Trial for Rare Complement-Mediated Kidney Diseases

Reuters
·
Sep 14

Akebia Therapeutics - Initial Data from Phase 2 Ebribafusp Trial Expected in 2027

THOMSON REUTERS
·
Sep 14

Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases

THOMSON REUTERS
·
Sep 14

Akebia Therapeutics Initiated at Buy by WestPark Capital

Dow Jones
·
Sep 08

Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Reuters
·
Sep 02

Akebia Grants New Hire Stock Options for 8,400 Shares at $0.92 Each

Reuters
·
Sep 02

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Sep 02

Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston

GlobeNewswire
·
Sep 01

Akebia Therapeutics Cut to Market Perform from Outperform by Leerink Partners

Dow Jones
·
Aug 08

Akebia downgraded to Market Perform from Outperform at Leerink

TIPRANKS
·
Aug 07

Akebia Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Akebia Q2 FY26 Turns to Net Loss of $8.9 Million; Revenue Falls 21.44% to $49.1 Million

Reuters
·
Aug 06

Akebia Q2 Revenue Falls on Lower Auryxia Sales

Reuters
·
Aug 06

Akebia Therapeutics Q2 EPS $(0.03) Beats $(0.04) Estimate, Sales $49.128M Beat $48.861M Estimate

Benzinga Earnings
·
Aug 06

Akebia Therapeutics Inc Expected to Post a Loss of 4 Cents a Share - Earnings Preview

Reuters
·
Aug 04

Akebia Grants 2 New Hires Options for 61,000 Shares at $1.32 Each

Reuters
·
Aug 04

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Aug 04

Akebia Initiates Phase 2 Basket Trial of Complement Inhibitor Ebribafusp in Rare Kidney Diseases

Reuters
·
Aug 03

Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases

THOMSON REUTERS
·
Aug 03